Tuxobertinib
| CAS No. | 2414572-47-5 | Cat. No. | BCP37532 |
| Name | Tuxobertinib | ||
| Synonyms | BDTX-189;BDTX 189; BDTX189; EGFR/HER2 inhibitor BDTX-189; ErbB mutant-specific inhibitor BDTX-189; | ||
| Formula | C29H29ClN6O4 | M. Wt | 561.04 |
| Description | BDTX-189 is an orally bioavailable, irreversible, selective, small-molecule inhibitor of certain oncogenic driver, allosteric mutations of the ErbB receptor tyrosine kinases epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/neu or ErbB2), including extracellular domain allosteric mutations of HER2, and EGFR and HER2 exon 20 insertion mutations, with potential antineoplastic activity. BDTX-189 selectively binds to and inhibits these allosteric ErbB mutants while sparing wild-type EGFR, which may result in the selective inhibition of cellular proliferation and angiogenesis in tumor cells and tumors expressing these allosteric ErbB mutations. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase Jak/Stat Pathway | ||
| Targets | EGFR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.